Mitchell C. Posner to Esophageal Neoplasms
This is a "connection" page, showing publications Mitchell C. Posner has written about Esophageal Neoplasms.
Connection Strength
5.357
-
For Gastroesophageal Junction Cancers, Does an "Esophageal" or "Gastric" Surgical Approach Offer Better Perioperative and Oncologic Outcomes? Ann Surg Oncol. 2020 Feb; 27(2):511-517.
Score: 0.584
-
An Update on Randomized Clinical Trials in Gastric Cancer. Surg Oncol Clin N Am. 2017 10; 26(4):621-645.
Score: 0.509
-
Transhiatal Esophagectomy for Esophageal Cancer. J Laparoendosc Adv Surg Tech A. 2016 Oct; 26(10):752-756.
Score: 0.471
-
Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010 Aug 14; 16(30):3804-10.
Score: 0.310
-
Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol. 2010 Mar 15; 101(4):299-304.
Score: 0.302
-
The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003 Aug; 4(8):481-8.
Score: 0.191
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.184
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.176
-
Standard surgical approaches in the management of esophageal cancer. Surg Oncol Clin N Am. 2002 Apr; 11(2):351-63.
Score: 0.174
-
Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer. Surgery. 2001 Oct; 130(4):620-6; discussion 626-8.
Score: 0.168
-
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. Arch Surg. 2001 Jul; 136(7):737-42; discussion 743.
Score: 0.165
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.158
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.150
-
Apoptosis in esophageal cancer following induction chemoradiotherapy. J Surg Res. 1998 Sep; 79(1):20-4.
Score: 0.136
-
p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998 Jul 01; 83(1):7-18.
Score: 0.134
-
Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am. 1998 Jul-Aug; 4(4):237-46.
Score: 0.134
-
Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr. 1998 Jan-Feb; 22(1):18-21.
Score: 0.129
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.127
-
Is esophagectomy following upfront chemoradiotherapy safe and necessary? Arch Surg. 1997 May; 132(5):481-5; discussion 485-6.
Score: 0.124
-
Extremes of body mass index and postoperative complications after esophagectomy. Dis Esophagus. 2017 May 01; 30(5):1-6.
Score: 0.124
-
Primary malignant melanoma of the esophagus. Am J Gastroenterol. 1996 May; 91(5):1048-9.
Score: 0.115
-
Doubling of 30-Day Mortality by 90 Days After Esophagectomy: A Critical Measure of Outcomes for Quality Improvement. Ann Surg. 2016 Feb; 263(2):286-91.
Score: 0.113
-
Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst. 2014 Jul; 106(7).
Score: 0.102
-
Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):2002-10.e1-2.
Score: 0.100
-
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
Score: 0.090
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.078
-
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol. 2009 Nov; 104(11):2684-92.
Score: 0.072
-
Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008 Feb; 6(2):159-64.
Score: 0.065
-
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 Apr 15; 65(8):3146-54.
Score: 0.054
-
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-89-S19-92.
Score: 0.032
-
Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996 Sep; 83(9):1174-85.
Score: 0.030
-
Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. Surgery. 1996 Jul; 120(1):45-53.
Score: 0.029
-
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
Score: 0.011
-
NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. 2000 Dec 15; 60(24):6958-63.
Score: 0.010
-
Peripheral athero-embolism from the aorta complicating transhiatal esophagectomy. Am Surg. 1994 Aug; 60(8):634-7.
Score: 0.006